Trials / Recruiting
RecruitingNCT07197450
Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism
Efficacy and Safety of mRNA Drug XH02 in the Treatment of Adult Hypoparathyroidism
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the safety and efficacy of a novel PTH replacement therapy drug in patients with hypoparathyroidism. The drug is an mRNA drug which will be translated into PTH after intravenous administration, to achieve the therapeutic effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intravenous administration of PTH1-84 mRNA | intravenous administration of PTH1-84 mRNA |
Timeline
- Start date
- 2025-05-20
- Primary completion
- 2026-04-15
- Completion
- 2026-04-30
- First posted
- 2025-09-29
- Last updated
- 2026-03-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07197450. Inclusion in this directory is not an endorsement.